Epilepsy Patients Face Crisis as Bedrolite Supplier Declares Bankruptcy
Families fear life-threatening seizures as Dutch cannabis oil supplies face imminent depletion.
1Supply Chain Collapse
The Dutch pharmaceutical company Bedrocan, the sole manufacturer of the specific cannabis oil Bedrolite, declared bankruptcy in October 2024. This insolvency threatens the continuity of treatment for UK patients with severe, drug-resistant epilepsy. Families now face a critical supply shortage as current inventory levels in the Netherlands are being restricted.
2Patient Vulnerability
For patients like 15-year-old Alfie Deacon, Bedrolite has been essential for remaining seizure-free for eight years. Before accessing this medication, Alfie suffered 150 seizures weekly, requiring frequent hospitalizations. His grandmother, Maggie Deacon, warns that losing access could force him back into a cycle of debilitating seizures and heavy steroid treatments.
3Life-Threatening Risks
Emma Matthews, whose 23-year-old son Louis relies on Bedrolite, describes the situation as a cliff-edge condition. Louis has previously experienced immediate seizure recurrence when stopping the medication. Families fear that a sudden cessation of the drug could lead to fatal outcomes, as alternative cannabis formulations do not provide the same efficacy.
4Export Restrictions
The Dutch government has reportedly halted exports of Bedrolite to prioritize domestic supply for its own citizens. While the UK currently holds approximately six months of stock, the lack of a reliable domestic production source leaves patients without a long-term safety net once these remaining supplies are exhausted in the coming months.
5Political Intervention
Labour MP Tonia Antoniazzi has formally contacted the UK health minister to demand government action regarding the supply crisis. She argues that the UK must develop the capacity to produce similar medicinal cannabis products domestically. This would reduce reliance on volatile international supply chains and protect vulnerable patients from future corporate bankruptcies.
6Government Response
The Department of Health and Social Care acknowledges the importance of uninterrupted access for patients using unlicensed cannabis-based products. Officials confirmed that sufficient stock exists for the short term but stated they are actively working with the UK supplier and Dutch authorities to determine if additional inventory can be secured for patients.
7Advocacy Efforts
Organizations including the MedCan Families Foundation and the Medical Cannabis Clinicians Society have urged the government to intervene immediately. These groups emphasize that the current reliance on a single foreign manufacturer is unsustainable. They are pushing for policy changes that ensure long-term stability for children whose lives depend on this specific medication.
8Historical Context
The campaign for Bedrolite access gained national attention in 2018 when Hannah Deacon successfully lobbied Downing Street for NHS prescriptions. Following her sudden death in 2024, her family continues her advocacy work. The current crisis highlights the fragility of medical access when patients depend on a single, non-domesticated pharmaceutical supply chain.